Houston-based Milkify will pitch their freeze-drying breast milk concept on Shark Tank this Friday. Photo courtesy of Milkify

A Houston startup is competing in the "Super Bowl of Business," as founder Pedro Silva calls it, and you can watch the action later this week.

Milkify will appear on ABC’s “Shark Tank” this Friday, April 7. Silva, co-founder and CEO, created Milkify along with his wife, Berkley Luck, PhD, in 2019. Today, Luck is a mom, COO, and a molecular biologist, but she had the idea for the company back in grad school. A coworker was struggling with pumping breast milk “lugging the pump back to work,” as Luck puts it.

Luck was studying probiotics at the time and was using a freeze-dryer in her work. The problem inspired her to create a process of freeze-drying breast milk that is now patent pending. The trademarked process is centered around SafeDry, special freeze-drying pouches.

“The breast milk never makes contact with our equipment,” Luck explains. The powdered milk is transferred directly from the bag in which it’s freeze-dried to the final packaging under sterile conditions. The result is not only shelf-stable, but keeps for at least three years, exponentially longer than frozen milk.

Silva admits that when Luck first pitched Milkify to him, he thought it was a crazy idea. “But Berkley is way smarter than I am. There must be something to it,” he realized. At the time, he was working in energy private equity. But he vowed that if they could find a viable path to making Milkify a business, he would join Luck full-time.

Early in the company’s life, the couple purchased a blue van that said “We will freeze-dry your breast milk,” recalls Silva. This grassroots marketing introduced them to a neighbor whose baby refused to drink her frozen milk. “He spat it out, he hated the taste,” Silva says. The pair freeze-dried her milk for the baby and their neighbor soon sent a video of the little one chugging six ounces of her rehydrated milk.

“That was the lightbulb moment,” says Silva. “How often do you get to work on something really meaningful?”

Since its founding, Milkify has freeze-dried and powdered more than half a million ounces of breast milk, all carefully preserved and packaged individually. Last October, Milkify opened what Luck claims is, “The only GMP-certified processing facility in the world right now specifically designed for freeze-drying breast milk.”

The 6,400-square-foot Houston space is a vast improvement from the previous 200-square-foot facility. That was thanks to raising $1.2 million in funds, which has also allowed them to build a larger staff.

“Our entire workforce at this point other than Pedro is moms,” says Luck. Including the couple, they are a team of 10, and just hired two additional members. They are currently looking to hire, says Silva, with roles including both operations and logistics associates. Experience, he says, is less important than conscientiousness and a good attitude, as they will train their new hires in-house.

And Milkify is about to receive more attention than ever with its appearance on “Shark Tank.” “Getting on a national stage to share our story was the main motivation for it,” says Luck. That translates to both education about the potential for freeze-drying breast milk, and about Milkify’s unique model.

“We started this business as a labor of love. It wasn’t just a financial reason,” says Silva. “This can actually help a lot of people. This is a way to spread the word.” And in the process, help countless moms and babies.

Berkley Luck and Pedro Silva — the wife and husband team behind Milkify — appear on Shark Tank this Friday. Photo courtesy of Milkify

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.